Procept BioRobotics opened lower at $23.28, compared with its previous close of $23.34. In the last trading session, the stock traded between $23.14 and $24.31. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Procept BioRobotics is now worth
$ 56.13
Resulting in a loss of
$ 43.87 (43.87%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
+$0.19 (+0.79%)
Day High
$24.31
Day Low
$23.14
Day Open
$23.28
Prev Close
$23.34
Volume
10,26,484
1W Return
8.66%
1M Return
20.09%
3M Return
2.80%
6M Return
-11.06%
1Y Return
-24.94%
Market Cap ($ Mn)
1,354
PE Ratio
-
PB Ratio
3.51
PEG Ratio
-
ROE
-24.85%
ROCE
-22.50%
EPS (TTM)
$-0.46
1 Week
8.66%
1 Month
20.09%
3 Months
2.80%
6 Months
-11.06%
9 Months
-17.46%
Truist raises PROCEPT BioRobotics price target to $24, keeps Hold
Truist Securities raises PROCEPT BioRobotics price target to $24 from $21. Analyst Richard Newitter maintains a Hold rating on the stock. UBS and Leerink Partners previously raised targets to $21 and $22 respectively. All three firms maintain neutral or market-perform stances despite higher targets.
6 days agoPROCEPT BioRobotics faces lawsuit over alleged sales inflation
Lawsuit filed July 24, 2026, alleging misrepresentation of business operations. Complaint claims undisclosed discount programs artificially inflated U.S. handpiece sales. Overstocking from bulk orders exposed company to operational and financial risks. Shareholders Foundation announced case on September 30, 2026, offering recovery options.
1mo agoPomerantz joins PROCEPT class action ahead of Sept 22 deadline
Pomerantz LLP joins the PROCEPT BioRobotics class action lawsuit regarding alleged securities fraud. Investors have until September 22, 2026, to serve as lead plaintiff for losses during the Class Period. Allegations center on undisclosed discount programs inflating sales and creating a 10,000-unit inventory glut. PROCEPT shares fell more than 75% from a high of $100.00 following serial disclosures of misleading data.
1mo agoBernstein Liebhard joins Procept BioRobotics class action lawsuit
Bernstein Liebhard LLP joins four other firms in the Procept BioRobotics class action lawsuit. Investors who bought shares between Feb 28, 2024, and Feb 25, 2026, are urged to act. Lead plaintiff motions must be filed by September 22, 2026. Lawsuit alleges misleading statements about handpiece sales and discount programs.
2mo agoTD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28
TD Cowen analyst Joshua Jennings keeps a Buy rating on PROCEPT BioRobotics (NASDAQ: PRCT) but cuts the price target from $34 to $28. The move adjusts valuation expectations while maintaining confidence in the company's long-term prospects within the BPH treatment market.
3mo agoPROCEPT BioRobotics to report Q2 2026 results on August 4
PROCEPT BioRobotics Corporation will announce its financial results for the second quarter of 2026 after market close on August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. The webcast and replay will be available on the company's website.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Procept BioRobotics is now worth
$ 56.13
Resulting in a loss of
$ 43.87 (43.87%)
Note: Past profits do not guarantee future returns.
